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Abstract: This review highlights the growing prominence of self-care and explores the contribu-
tion of community pharmacy. Firstly, background to self-care is discussed, followed by placing 
self-care in context with regard to the general public and accessing community  pharmacy. From 
this perspective the contribution community pharmacy currently makes is assessed, paying 
particular attention to the factors that negatively impact on the ability of community pharmacy 
to facilitate self-care.
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What is self-care?
Fundamentally, the concept “self-care” puts responsibility on individuals for their 
own health and well-being. Many authors have described what constitutes self-care, 
and whilst no universally agreed definition exists, it is clear that self-care is seen as a 
broad concept that encompasses activities to establish and maintain health, through to 
preventing ill health.1 The World Health Organization defines self-care as “the abil-
ity of individuals, families and communities to promote health, prevent disease, and 
maintain health and to cope with illness and disability with or without the support of 
a health-care provider”.2
In its broadest sense, self-care is therefore any action or activity individuals or 
communities do to maintain both physical and mental health. Many authors have 
investigated people’s perception of health and illness and how that might manifest into 
taking action.3–6 This will vary enormously and depend on how individuals perceive 
themselves and the environment around them. People tend to weigh up the benefit they 
attach to good health versus the “cost” of accomplishment, as has been encapsulated 
in the “health belief ” model.7
Self-care has been described as a continuum (Figure 1), starting with individual 
choices on health (eg, taking exercise), moving through to managing their own ill 
health (eg, self-medicating) either on their own or with help. As people progress 
along the continuum, more facilitation by others is required until a person needs fully 
managed care.
What is self-medication?
“Self-medication” is just one element of self-care and can be defined as the 
selection and use of medicines by individuals to treat self-recognized illness 
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or symptoms. How these medicines are made available 
to the public varies from country to country but all have 
been approved by regulatory agencies as safe and effec-
tive for people to select and use without the need for 
medical supervision or intervention. Products come with 
comprehensive labeling, and evidence suggests that the 
majority of consumers will read this information before 
taking a new medicine.8 Whether the decisions made are 
correct is largely unknown.
Self-selection medicines are commonly referred to 
as “over-the-counter” medicines or “nonprescription” 
 medicines. In this review, the term “nonprescription” will 
be adopted since different markets place varying restrictions 
on their availability, but all fall under the umbrella term of 
“nonprescription”.
Facilitated self-medication
The majority of purchases for nonprescription medicines are 
by the consumer alone using product information from pack-
aging to make an informed decision on whether to purchase. 
When consumers seek help at the point of purchase, this can 
be termed “facilitated self-medication”. Where medicines are 
purchased through pharmacies, staff are in a strong position 
to facilitate self-care decision making by consumers, as in 
most pharmacies the transaction takes place through a trained 
counter assistant or the pharmacist. Limited research has 
shown that consumer-purchasing decisions are affected by this 
“facilitation”. Nichol et al9 and Sclar et al10 both demonstrated 
that consumers (25% and 43%, respectively) altered their pur-
chasing decision when proactively approached by pharmacy 
students. Furthermore, a small proportion of consumers did 
not purchase anything (13% and 8%, respectively) or were 
referred to their doctor (1% and 4%, respectively).9,10 These 
studies highlight how the pharmacy team is able to positively 
shape consumer decisions and help guide consumers to 
alternative (and arguably better) alternatives.
The prominence of self-care
Self-care is not new; people have always taken an active 
role in their own health. What is different now is the attitude 
toward self-care by policy makers, health care organizations, 
not-for-profit agencies, and frontline health care workers. 
Health improvements have been seen in people adopting 
health-enhancing behaviors rather than just through medical 
intervention. This has led to self-care being seen in a broader 
context than just the way in which people deal with everyday 
illness. Of course, health outcomes are not the only reason 
why there has, and continues to be, a resurgence in self-care. 
Twenty-five years ago, Coons spoke of increasing health care 
costs, changes in societal lifestyle, improved educational 
levels, and increasing consumerism – all as valid today as 
they were then.11 Fundamentally, there are two major drivers 
affecting self-care: consumerism and costs.
Consumerism
As Coons discussed, changes in society have led to people 
having a different outlook on health and the way in which 
individuals perceive their own health/ill health.11 Yet today’s 
world is very different to that experienced by Coons, espe-
cially with regard to access to information. The creation of 
the Internet and almost instantaneous access to limitless data 
on all aspects of health and care means that people across the 
globe have the means to query decisions and challenge medi-
cal opinion. This growing empowerment is also influenced by 
greater levels of education; having information is one thing 
but being able to understand it and utilize it is another. This 
has proved challenging to health care systems and workers, 
having to move from traditional structures and paternalistic 
doctrines (eg, “doctor knows best”) to a patient-focused 
and -centered type of care. For example, medicine taking 
has shifted from compliance to adherence,12 and medical 
consultations now advocate “shared decision making”.13 This 
heightened public awareness about health, in the context of 
self-care, allows individuals to make informed choices and 
recognize that much can be done by themselves. The extent 
of self-care is none better exemplified than by the level of 
consumer self-medication. The use of nonprescription medi-
cines is the most prevalent form of medical care in the world.14 
Sales are huge, with the global market estimated to be worth 
€73 billion.15 Markets in Western Europe and the USA make 
up almost half of all sales, but growth in these markets has 
slowed – even so, the average spend per capita in Western 
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Figure 1 The self-care continuum.
Reproduced with kind permission from the Self Care Forum.
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Europe is €68. Emerging markets in Central and Eastern 
Europe, the People’s Republic of China, Russia, and India now 
represent major growth areas for nonprescription medicines. 
Fuelled by these markets, nonprescription medicines have 
seen greater sales growth than that of prescription medicines 
since 2008.
Understanding consumer-purchasing patterns in such 
a large market is vital to the pharmaceutical industry, but 
equally as important to community pharmacy, both from 
the point of view of maximizing revenue and having the 
opportunity to provide facilitated self-medication. Despite 
the enormous sums of money spent on nonprescription 
medicines, approximately only 25% of people regularly 
purchase nonprescription medicines (25% tend to seek 
medical attention, and 50% do nothing).16–18 The extent to 
which this happens does vary from country to country, and 
in some markets this is considerably higher – for example, in 
South Africa and the USA, where 35%–40% of people use 
nonprescription medications on a regular basis.8
Most people have high levels of confidence in the prod-
ucts they take, believing them to be effective and as good 
as prescription medicines.19,20 This seems to stem from prior 
positive use of the product, with most consumers using the 
same product for subsequent episodes of the same  illness. 
In effect, they build up a small “formulary” of trusted 
medicines.18,21
Many papers and commissioned reports show that access 
and convenience shape the purchasing patterns of  consumers. 
These factors seem to be unaffected by country or time. 
Reports spanning 30 years have repeatedly concluded that 
these play an important part in consumer decision making, 
and are probably the major reason why consumers buy non-
prescription medicines.22,23 The element of convenience does 
have a country context – for example, in Western countries, 
this is primarily due to ease of access that negates the need 
for doctor seeking, which is often associated with higher cost 
and increased time. In developing countries, “convenience” 
is more associated with “need” due to lower levels of health 
infrastructure and access to medical resources.
Although, some differences exist in why nonprescrip-
tion medicines are bought, the range of signs and symptoms 
experienced by people is not country specific. It appears 
that minor illnesses have no geographic boundaries and the 
same problems are seen the world over. Respiratory prob-
lems (coughs, colds, sore throats), pain disorders (headache, 
musculoskeletal), and gastrointestinal disturbances are three 
therapeutic areas that consistently rank as the most prevalent 
problems seen in all markets and this is reflected in product 
sales data.8 The way in which consumers decide on particular 
courses of action is primarily influenced by the perception 
of symptoms experienced, severity, and duration.24–26 Market 
research surveys have highlighted that consumers strongly 
exhibit certain health-seeking behaviors depending on the 
signs and symptoms experienced. For example, bleeding from 
the rectum is almost exclusively associated with consulting a 
doctor, as too are symptoms like arthritis, cystitis, and those 
of a depressive type.27 In contrast, headache, indigestion, 
coughs and colds, minor skin problems (eg, insect bites, 
sunburn) are mostly self-treated with no advice from any 
health care professional.8,15,19 Consumers therefore attach 
“seriousness” to symptoms and act according to the perceived 
level of seriousness.
Costs
As populations across the globe begin to live longer, whether 
through better hygiene, nutrition, or advances in medicine, 
the provision of medical care is becoming more and more 
expensive.28 In an attempt to control costs, many countries 
have gone through major health care reforms to maximize 
existing both financial and human resources to deliver effec-
tive and efficient health care.29–32 These reforms include 
integrating self-care into mainstream public health policy, 
including the management of long-term conditions.
We already know that patients self-manage problems to 
a large extent,33 but encouraging more people to exercise 
greater levels of self-care, either for acute or chronic prob-
lems, has the potential to shift costs away from professional 
care, as minor changes in behavior have significant potential 
to affect demand for formal health care.
Figures from the UK give some indication as to the 
magnitude of potential cost savings. Take primary care 
workload as an example. It is reported that approximately 
20%–40% of general practice (GP) workload constitutes 
patients seeking help for minor illness.34 Pillay et al attempted 
to quantify cost savings to the UK National Health Service 
if minor ailment consultations were transferred to commu-
nity pharmacy rather than being seen in GP.35 An estimated 
57 million consultations were categorized as being for 
minor illness presentations. Factoring staff and medicine 
costs, they conservatively estimated that the economic bur-
den to the National Health Service was £2 billion. Whilst 
shifting all such consultations away from GP is unrealistic, 
even if a small proportion of patients could be managed 
via self-care then cost savings would be very considerable. 
Utilization of health care resources where self-care could 
have been exercised has also been noted for accident and 
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emergency  presentations. Bednall et al estimated that 8% 
of attendees (n2,636) could have been managed through 
a community pharmacy.36  Findings from a recent UK com-
missioned report that the relative costs for accessing differ-
ent levels of health care were significantly cheaper through 
pharmacy services (£29 compared with £82 for GP and £147 
for emergency hospital visits).37
Contribution of community 
pharmacy to self-care
Community pharmacists are uniquely placed to provide sup-
port and advice to the general public compared with other 
health care professionals. The combination of location and 
accessibility means that most consumers have ready access 
to a pharmacy where health professional advice is available 
on demand. A high level of public trust and confidence in 
pharmacists’ ability to advise on nonprescription medicines 
is afforded to community pharmacists.38 Although there is a 
general global move to liberalize nonprescription markets, 
pharmacies in many countries still are the main suppliers of 
nonprescription medicines.15 Pharmacists are therefore in a 
position to facilitate consumer self-care and self-medication, 
which needs to be built on and exploited.
Managing minor illness –  
medicine reclassification
Global health care policy, as previously mentioned, now has 
a strong self-care focus and various strategies have been put 
in place to encourage consumers (and pharmacists) to have 
a more active role in exercising self-care.
The most notable long-term global health care policy, 
which directly affects pharmacy, is the reclassification of 
 prescription-only medicines as nonprescription medicines.39–43 
In many countries (eg, Australia, New Zealand, France, 
Sweden, Canada, UK) regulatory frameworks support reclas-
sification by having a gradation in the level of medicine avail-
ability, whereby certain medicines can only be purchased at 
a pharmacy. These “pharmacy medicines” usually have to 
be sold either by the pharmacist or under their supervision. 
Other countries operate a two-category system (prescription/
nonprescription), such as that seen in the USA. Over the last 
30 years this approach has seen a wide range of therapeutic 
agents made available to consumers, including emergency 
hormonal contraception (and in 2015, ellaOne® [ulipristal 
acetate] will also be available in the European Union), proton 
pump inhibitors, triptans, and beta-2-agonists.
Pharmacies unquestionably handle and manage large 
numbers of consumers who seek help and advice for minor 
illness, and advocates of pharmacy have argued that this will 
decrease doctor workload regarding minor illness, allowing 
them to concentrate more on “complex” patient care. To date, 
most reclassifications have involved medicines that are used 
to treat acute problems. However, recent reclassifications 
have strayed into the area of medicines for the management 
of long-term conditions. Statins, orlistat, and tamsulosin 
are now available in some markets.44 These medicines may 
herald the beginning of a new era in nonprescription avail-
ability, whereby pharmacists will be able to manage long-
term conditions.
The expansion of nonprescription medicines has undoubt-
edly contributed to the growth seen in the market and given 
consumers greater choice. It has also provided community 
pharmacy with an opportunity to demonstrate real and tan-
gible benefits to consumers by facilitating patient self-care. 
However, research data on the impact community pharmacy 
has on patient outcomes through facilitated self-medication 
are lacking when compared with those on patient self-care. 
Yet in more formalized situations where community phar-
macy delivers self-care, there is more credible research 
evidence to show the positive contribution it makes. For 
example, in the UK, government-endorsed (and -funded) 
schemes such as the minor ailment schemes and Healthy Liv-
ing Pharmacies have shown the positive impact community 
pharmacy can have.45,46
Barriers to community pharmacy 
exercising self-care
Great strides have been made in recent years in transforming 
community pharmacy from “merely” dispensers and sellers 
of medicines. However, there is still a multitude of problems 
associated with increasing the contribution pharmacy makes 
to self-care. Most, if not all, have been repeatedly reported 
on, and successive professional or government reports have 
tended to advocate the same recommendations. History in 
this respect seems to be repeating. Many of these obstacles 
are unfortunately, though, of pharmacy’s own making.
Pharmacists as a barrier to self-care
Is pharmacy ready to be seen by policy makers, consumers, 
and other health care providers as a credible alternative to 
delivering patient-focused services? It is first necessary to 
know how willing pharmacy is to practice change. Many 
countries have produced “road maps” or “blueprints” to 
becoming more patient focused,47–50 but translating these 
into actual practice has proven slow and problematic.51–57 
For example, 10 years after the introduction of the Medicines 
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Use Review in the UK, approximately only 75% of the total 
potentially available reviews had been performed.58 When 
looking at adoption of change and delivery of new services, 
it is unclear why they are not more universally adopted. 
However, as stated by Rogers59 in his book Diffusion of 
Innovations, typically only 2.5% of a population performs 
as innovators and 13.5% will be early adopters. Using this 
premise then, the majority of pharmacists will not be recep-
tive to change even when provided with the right conditions. 
Research reporting on the introduction of new cognitive 
services often cites predictable barriers to practice change, 
including issues such as time, funding, and limited support. 
Rosenthal et al considered the culture of pharmacy to explain 
this reluctance to change.60 They argued that pharmacists’ 
lack of confidence in their own clinical ability and fear of 
taking on responsibility and accountability are stifling the 
ability of the profession to take on these new challenges. This 
viewpoint appears to be grounded in reasonable evidence. 
Multiple studies that have investigated role extension or the 
provision of new services consistently report on pharmacists’ 
self-assessment for the need for training and reluctance to 
make autonomous decisions.61–63
The literature seems to suggest that pharmacists them-
selves are a major barrier to adopting behaviors that would 
allow facilitated self-care and self-medication.
Pharmacists’ inability  
to facilitate self-care
Regardless of what degree of control is placed on medicine 
availability in different countries, pharmacists can now 
manage and treat a wider number of conditions than ever 
before. This raises the question as to whether pharmacists 
are capable of selling these medicines appropriately. 
Early research into pharmacist–consumer interactions in 
pharmacy practice did not address this but concentrated 
more on auditing questioning behavior and analyzing the 
advice people received. This body of work did illustrate the 
basic nature of performance – the types of question asked, 
frequency of advice provided, and consumer perception 
to questioning. The findings were broadly critical of phar-
macist performance.64–69 Over the same time period, covert 
investigation by the UK consumer organization Which? 
also concluded that pharmacists generally performed 
poorly.70–72 Further practice research (mainly from developed 
 countries) has sought to determine the outcomes rather than 
the mechanics of the interactions. Findings from all papers 
raise questions over pharmacist ability. Lamsam and Kropff 
found that in a third of interactions the pharmacists made 
 recommendations without assessing the patient’s symptoms 
and in a further third of cases recommendations were poor, 
which could have potentially caused harm.73 Rutter et al 
found that the expected outcome was only reached in half 
of observed cases.74 Driesen and Vandenplas75 and Bilkhu 
et al76 also reported poor performance, and each study (on 
diarrhea in a baby and allergic conjunctivitis in an adult, 
respectively) suggested that too few questions were asked. 
Tucker et al compared pharmacist performance with that 
off doctors and nurses across a spectrum of dermatologi-
cal  conditions.77 Pharmacists performed more poorly than 
doctors and only 40% of pharmacists were able to identify 
all lesions correctly.77 Data from developing countries 
are limited but a review by Brata et al also highlighted 
inconsistent information gathering leading to inappropriate 
 recommendations.78 The use of protocols/guidelines and 
mnemonics seems to have been almost universally adopted 
by pharmacy, yet performance using these “decision aids” 
seems to have little impact on improving performance.79–84 
A recent review of mnemonics by Shealy concluded that 
“ultimately, use of these tools can aid the provider in 
obtaining information from patients in immediate need cir-
cumstances, and improve the quality of care”.85 These tools 
might allow for standardizing the information gained from 
the patient; the more important question, however, is how 
do pharmacists utilize that information? Having a set of data 
still requires that dataset to be interpreted – this is where the 
problem seems to lie. Recent research findings on investigat-
ing pharmacist diagnostic decision making have shown that 
community pharmacists show poor clinical reasoning due to 
over reliance on protocol-driven questioning.86–88
In attempt to drive standards up, some pharmacy orga-
nizations employ mystery shopper techniques to monitor 
standards of practice.90 Compounding these findings of sub-
optimal performance is with whom the interaction occurs. 
Most consultations are solely handled by non-pharmacist 
staff, who have been shown to perform more poorly than 
pharmacists.23,90–93 It would seem logical, then, to involve 
the pharmacist earlier and more frequently in consultations. 
This raises questions over the level of importance placed on 
differing pharmacy tasks and the appropriate use of staff in 
community pharmacies. Data over the last 20 years suggest 
that pharmacists still spend the largest amount of their time 
in non-patient-focused activity.94 Undoubtedly this is dictated, 
in large part, by prescription volume, but it also suggests a 
reluctance to move out of the dispensary.
It appears that pharmacists’ ability to consistently and 
appropriately facilitate self-care through managing people 
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requesting advice on signs and symptoms has improved little 
over the last 25 years.95
Despite pharmacy’s own failings, the operating environ-
ment in which pharmacy contributes to self-care also poses 
major challenges. Community pharmacy is at the interface 
between consumer self-care and managed care, and often acts 
as a filtering mechanism between the two. Unfortunately, 
this remains almost exclusively an informal arrangement 
between pharmacy and primary medical services. This 
hinders facilitated self-medication and acceptance from 
doctors toward community pharmacists delivering more 
patient-focused care. Several studies have been conducted 
on doctor opinion in this regard. Overall, doctors are very 
receptive to pharmacists providing greater levels of support 
to medicine-specific tasks (eg, assisting with compliance, 
providing medicines information, cost-effective prescribing). 
However, it appears they are less willing to endorse services, 
which are traditionally associated with GP.62
Specific to self-medication, doctors (and nurses to a lesser 
extent) have been canvassed about the wider availability of 
medicines. Broadly speaking doctors have become, over 
time, more supportive of wider medicine availability.96–99 
Similar views have been noted for nurses with prescribing 
rights.100 This is especially true for deregulated medicines 
to treat acute conditions. In contrast, doctors and nurses are 
much more reluctant to accept nonprescription availability 
of medicines to treat chronic conditions. For both groups of 
health care professionals, major doubts exist over the phar-
macist’s ability to have the necessary information from which 
to make decisions and conduct subsequent monitoring after 
initial medicine supply. These strong beliefs mean that in the 
short-term it seems unlikely that management by pharmacists 
of patients with long-term conditions will happen unless more 
integrated and formal mechanisms of sharing information 
are established. One possible solution to overcome these 
reservations would be to draw on models of medicine supply 
elsewhere. For example, countries such as New Zealand and 
Australia have an “intermediary” category of medicine that 
has to be sold by the pharmacist.101 This system could provide 
the reassurances required by other health care practitioners 
that adequate safeguards were in place for the patient to be 
successfully managed through the pharmacy.
Conclusion
Pharmacy has a long history of facilitating self-care, but 
now more than ever before pharmacists and their staff are 
being provided opportunities to expand their contribution. 
Yet considerable barriers still exist if community pharmacy is 
to maximize its potential. From within the profession, ques-
tions have to be asked about pharmacists’ ability and readi-
ness to embrace change. From other health care providers, 
the issue is one of reluctance to allow pharmacy to take on 
greater responsibility. New health care pathways providing 
easier transition through the self-care continuum that bring 
the consumer, pharmacist, and primary medical services 
together are needed.
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